Current Opinion in Lipidology, Journal Year: 2025, Volume and Issue: unknown
Published: April 23, 2025
Purpose of review Remnant cholesterol is receiving increasing attention as a target to reduce residual atherosclerotic cardiovascular disease (ASCVD) risk in individuals already treated with statins. New therapeutic options antisense oligonucleotides, small interfering RNA, and monoclonal antibodies allow specific targeting genes proteins counter pathological pathways promoted by these genes. Identifying genetic determinants remnant relating ASCVD thus an appealing path identifying evaluating new existing drug targets. Recent findings Human epidemiology has identified several variants involved lipoprotein metabolism effect on plasma concentrations cholesterol. Lipoprotein lipase (LPL) central the lipoproteins cholesterol, genes, including APOC3 , ANGPTL3 ANGPTL4 whose gene products regulate activity LPL, are important Summary Current opinion that likely causal factor development ASCVD. studies have many LPL function, affecting concentrations, some which used targets, others subject investigation their triglyceride-lowering clinical trials.
Language: Английский